|
Declining R&D productivity, ballooning development costs, and increasing product lead times pose significant challenges for life science and medical device companies striving to fill product pipelines and meet growth expectations. Even when compounds and devices have passed through the regulatory process, pricing pressure from payers and the competitive landscape make it difficult to position and launch new products. Generics and shorter-market exclusivity windows are threatening revenues. At the same time, these pressures provide opportunities for innovative companies as competition increases amongst mature cashed-up companies trying to access good innovation.
To help our clients meet the many challenges they face, L.E.K. provides a full array of expert services, including corporate strategy, product strategy, and transaction services. We help companies innovate, fund, develop, market, and launch ground-breaking products in an environment where raising capital is increasingly costly and competition is fierce. For example:
A public biotechnology company needed to increase R&D productivity... more
L.E.K. helped a leading developer of pharmaceutical products expand into new therapeutic areas... more
A U.S.-based biopharmaceutical company on the verge of launching a new cancer drug needed to balance investment in future growth against market expectations for earnings and revenue performance... more
To uncover and create new opportunities, and assess and mitigate potential risks, clients turn to L.E.K. for assistance in addressing the full spectrum of life sciences specialties, including:
- Biotechnology
- MedTech
- Diagnostics
- Genomics and proteomics
- Imaging technologies
- Pharmaceuticals
- Specialty pharmaceuticals
- Generic pharmaceuticals
- Surgical products
- E-health
|
|
|
.jpg)
